Fusion protein linkers: Property, design and functionality

Advanced Drug Delivery Reviews

Volumn 65, Issue 10, 2013, Pages 1357-1369

  Chen, Xiaoying ^a   Zaro, Jennica L ^a   Shen, Wei Chiang ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bifunctional recombinant proteins; Pharmacodynamics; Pharmacokinetics; Spacer

Indexed keywords

BI-FUNCTIONAL; DESIGN AND APPLICATION; FLEXIBLE LINKERS; FUNCTIONAL DOMAINS; FUSION PROTEINS; MULTI DOMAINS; PHARMACOKINETIC PROFILES; SPACER;

BIOACTIVITY; DESIGN; PHARMACODYNAMICS; PHARMACOKINETICS;

PROTEINS;

ANTINEOPLASTIC AGENT; CASPASE 3 GRANZYME B SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; CLEAVAGE LINKER; FLEXIBLE LINKER; HYBRID PROTEIN; PEPTIDES AND PROTEINS; RECOMBINANT PROTEIN; RIGID LINKER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING SITE; BIOLOGICAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS;

AA; AMINO ACID; ANTIBODY HEAVY CHAIN VARIABLE REGION; ANTIBODY LIGHT-CHAIN VARIABLE REGIONS; BIFUNCTIONAL RECOMBINANT PROTEINS; COAGULATION FACTOR IX; EBFP; EGFP; ENHANCED BLUE FLUORESCENT PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; FIX; FLUORESCENT RESONANCE ENERGY TRANSFER; FRET; G-CSF; GRANULOCYTE COLONY-STIMULATING FACTOR; HGH; HSA; HUMAN GROWTH HORMONE; HUMAN SERUM ALBUMIN; IFN; INTERFERON; LAP; LATENCY ASSOCIATED PEPTIDE; MATRIX METALLOPROTEINASE; MMP; PD; PDB; PHARMACODYNAMIC; PHARMACODYNAMICS; PHARMACOKINETIC; PHARMACOKINETICS; PK; PROTEIN DATA BANK; SCFV; SINGLE-CHAIN VARIABLE FRAGMENT; SPACER; TF; TGN; TRANS-GOLGI NETWORK; TRANSFERRIN; V(H); V(L);

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

EID: 84881018686     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.039     Document Type: Review

References (85)

1. Terpe K. Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl. Microbiol. Biotechnol. 2003, 60:523-533.
2. Yuste R. Fluorescence microscopy today. Nat. Methods 2005, 2:902-904.
3. Schmidt S.R. Fusion-proteins as biopharmaceuticals-applications and challenges. Curr. Opin. Drug Discov. Devel. 2009, 12:284-295.
4. Chen X., Zaro J.L., Shen W.C. Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin. Drug Metab. Toxicol. 2012, 8:581-595.
5. Kim B., Zhou J., Martin B., Carlson O., Maudsley S., Greig N., Mattson M., Ladenheim E., Wustner J., Turner A., Sadeghi H., Egan J. Transferrin fusion technology: a novel approach to prolong biological half-life of insulinotropic peptides. J. Pharmacol. Exp. Ther. 2010, 334:682-692.
6. Weimer T., Wormsbächer W., Kronthaler U., Lang W., Liebing U., Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb. Haemost. 2008, 99:659-667.
7. Dumont J.A., Low S.C., Peters R.T., Bitonti A.J. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006, 20:151-160.
8. Schellenberger V., Wang C., Geething N., Spink B., Campbell A., To W., Scholle M., Yin Y., Yao Y., Bogin O., Cleland J., Silverman J., Stemmer W. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 2009, 27:1186-1190.
9. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 8:E532-E551.
10. Manoukian G., Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin. Biol. Ther. 2009, 9:1445-1451.
11. Pardridge W.M. Biopharmaceutical drug targeting to the brain. J. Drug Target. 2010, 18:157-167.
12. Patel L.N., Zaro J.L., Shen W.C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 2007, 24:1977-1992.
13. Widera A., Norouziyan F., Shen W.C. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv. Drug Deliv. Rev. 2003, 55:1439-1466.
14. Leader B., Baca Q., Golan D. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 2008, 7:21-39.
15. McDermott M.F. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today (Barc.) 2009, 45:423-430.
16. Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann. N. Y. Acad. Sci. 2011, 1222:55-63.
17. Zhao H., Yao X., Xue C., Wang Y., Xiong X., Liu Z. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering. Protein Expr. Purif. 2008, 61:73-77.
18. Amet N., Lee H.F., Shen W.C. Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm. Res. 2009, 26:523-528.
19. Bai Y., Ann D.K., Shen W.C. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7292-7296.
20. Bai Y., Shen W.C. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm. Res. 2006, 23:2116-2121.
21. Gokhale R.S., Khosla C. Role of linkers in communication between protein modules. Curr. Opin. Chem. Biol. 2000, 4:22-27.
22. Ikebe M., Kambara T., Stafford W.F., Sata M., Katayama E., Ikebe R. A hinge at the central helix of the regulatory light chain of myosin is critical for phosphorylation-dependent regulation of smooth muscle myosin motor activity. J. Biol. Chem. 1998, 273:17702-17707.
23. Argos P. An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J. Mol. Biol. 1990, 211:943-958.
24. George R., Heringa J. An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng. 2002, 15:871-879.
25. Williamson M.P. The structure and function of proline-rich regions in proteins. Biochem. J. 1994, 297(Pt 2):249-260.
26. Turner S., Russell G., Williamson M., Guest J. Restructuring an interdomain linker in the dihydrolipoamide acetyltransferase component of the pyruvate dehydrogenase complex of Escherichia coli. Protein Eng. 1993, 6:101-108.
27. Mottram J.C., North M.J., Barry J.D., Coombs G.H. A cysteine proteinase cDNA from Trypanosoma brucei predicts an enzyme with an unusual C-terminal extension. FEBS Lett. 1989, 258:211-215.
28. Aurora R., Creamer T., Srinivasan R., Rose G. Local interactions in protein folding: lessons from the alpha-helix. J. Biol. Chem. 1997, 272:1413-1416.
29. Bird R., Hardman K., Jacobson J., Johnson S., Kaufman B., Lee S., Lee T., Pope S., Riordan G., Whitlow M. Single-chain antigen-binding proteins. Science 1988, 242:423-426.
30. Sabourin M., Tuzon C., Fisher T., Zakian V. A flexible protein linker improves the function of epitope-tagged proteins in Saccharomyces cerevisiae. Yeast 2007, 24:39-45.
31. de Bold M.K., Sheffield W.P., Martinuk A., Bhakta V., Eltringham-Smith L., de Bold A.J. Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris. Regul. Pept. 2012, 175:7-10.
32. Waldo G., Standish B., Berendzen J., Terwilliger T. Rapid protein-folding assay using green fluorescent protein. Nat. Biotechnol. 1999, 17:691-695.
33. Maeda Y., Ueda H., Kazami J., Kawano G., Suzuki E., Nagamune T. Engineering of functional chimeric protein G-Vargula luciferase. Anal. Biochem. 1997, 249:147-152.
34. Arai R., Ueda H., Kitayama A., Kamiya N., Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001, 14:529-532.
35. Arai R., Wriggers W., Nishikawa Y., Nagamune T., Fujisawa T. Conformations of variably linked chimeric proteins evaluated by synchrotron X-ray small-angle scattering. Proteins 2004, 57:829-838.
36. Bhandari D., Levine B., Trayer I., Yeadon M. 1H-NMR study of mobility and conformational constraints within the proline-rich N-terminal of the LC1 alkali light chain of skeletal myosin. Correlation with similar segments in other protein systems. Eur. J. Biochem. 1986, 160:349-356.
37. Evans J., Levine B., Trayer I., Dorman C., Higgins C. Sequence-imposed structural constraints in the TonB protein of E. coli. FEBS Lett. 1986, 208:211-216.
38. Morris A., MacArthur M., Hutchinson E., Thornton J. Stereochemical quality of protein structure coordinates. Proteins 1992, 12:345-364.
39. Chen X., Bai Y., Zaro J., Shen W.C. Design of an in vivo cleavable disulfide linker in recombinant fusion proteins. Biotechniques 2010, 49:513-518.
40. Amet N., Wang W., Shen W.C. Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J. Control. Release 2010, 141:177-182.
41. Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N., Watson G.J., Knyba R.E., Wawrzynczak E.J., Blakey D.C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 1987, 47:5924-5931.
42. Zhao H.L., Xue C., Du J.L., Ren M., Xia S., Liu Z.M. Balancing the pharmacokinetics and pharmacodynamics of interferon-alpha2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy. Mol. Pharm. 2012, 9:664-670.
43. Crasto C.J., Feng J.A. LINKER: a program to generate linker sequences for fusion proteins. Protein Eng. 2000, 13:309-312.
44. Kabsch W., Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983, 22:2577-2637.
45. Hagemeyer C.E., von Zur Muhlen C., von Elverfeldt D., Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb. Haemost. 2009, 101:1012-1019.
46. Huston J., Levinson D., Mudgett-Hunter M., Tai M., Novotný J., Margolies M., Ridge R., Bruccoleri R., Haber E., Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5879-5883.
47. Trinh R., Gurbaxani B., Morrison S.L., Seyfzadeh M. Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression. Mol. Immunol. 2004, 40:717-722.
48. Reddy S.T., Ge X., Miklos A.E., Hughes R.A., Kang S.H., Hoi K.H., Chrysostomou C., Hunicke-Smith S.P., Iverson B.L., Tucker P.W., Ellington A.D., Georgiou G. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 2010, 28:965-969.
49. Alfthan K., Takkinen K., Sizmann D., Söderlund H., Teeri T.T. Properties of a single-chain antibody containing different linker peptides. Protein Eng. 1995, 8:725-731.
50. Takamatsu N., Watanabe Y., Yanagi H., Meshi T., Shiba T., Okada Y. Production of enkephalin in tobacco protoplasts using tobacco mosaic virus RNA vector. FEBS Lett. 1990, 269:73-76.
51. Werner S., Marillonnet S., Hause G., Klimyuk V., Gleba Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein A. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17678-17683.
52. Lu P., Feng M.G. Bifunctional enhancement of a beta-glucanase-xylanase fusion enzyme by optimization of peptide linkers. Appl. Microbiol. Biotechnol. 2008, 79:579-587.
53. Zhao H., Xue C., Wang Y., Li X., Xiong X., Yao X., Liu Z. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation. J. Biotechnol. 2007, 131:245-252.
54. McCormick A., Thomas M., Heath A. Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120. J. Infect. Dis. 2001, 184:1423-1430.
55. Bergeron L.M., Gomez L., Whitehead T.A., Clark D.S. Self-renaturing enzymes: design of an enzyme-chaperone chimera as a new approach to enzyme stabilization. Biotechnol. Bioeng. 2009, 102:1316-1322.
56. Shah D., Shen W.C. The establishment of polarity and enhanced transcytosis of transferrin receptors in enterocyte-like Caco-2 cells. J. Drug Target. 1994, 2:93-99.
57. Duttaroy A., Kanakaraj P., Osborn B., Schneider H., Pickeral O., Chen C., Zhang G., Kaithamana S., Singh M., Schulingkamp R., Crossan D., Bock J., Kaufman T., Reavey P., Carey-Barber M., Krishnan S., Garcia A., Murphy K., Siskind J., McLean M., Cheng S., Ruben S., Birse C., Blondel O. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005, 54:251-258.
58. Halpern W., Riccobene T., Agostini H., Baker K., Stolow D., Gu M., Hirsch J., Mahoney A., Carrell J., Boyd E., Grzegorzewski K. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm. Res. 2002, 19:1720-1729.
59. Schulte S. Half-life extension through albumin fusion technologies. Thromb. Res. 2009, 124(Suppl. 2):S6-S8.
60. Martel-Pelletier J., Welsch D.J., Pelletier J.P. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 2001, 15:805-829.
61. Lampert K., Machein U., Machein M.R., Conca W., Peter H.H., Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am. J. Pathol. 1998, 153:429-437.
62. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998, 21:75-80.
63. Leppert D., Lindberg R.L., Kappos L., Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 2001, 36:249-257.
64. Vessillier S., Adams G., Chernajovsky Y. Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3. Protein Eng. Des. Sel. 2004, 17:829-835.
65. Wakefield L.M., Winokur T.S., Hollands R.S., Christopherson K., Levinson A.D., Sporn M.B. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J. Clin. Invest. 1990, 86:1976-1984.
66. Vessillier S., Adams G., Montero-Melendez T., Jones R., Seed M., Perretti M., Chernajovsky Y. Molecular engineering of short half-life small peptides (VIP, alphaMSH and gammaMSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Ann. Rheum. Dis. 2012, 71:143-149.
67. Adams G., Vessillier S., Dreja H., Chernajovsky Y. Targeting cytokines to inflammation sites. Nat. Biotechnol. 2003, 21:1314-1320.
68. Park J.H., Yamaguchi Y., Inouye M. Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a cleavable linker by specific proteases. Appl. Environ. Microbiol. 2012, 78:3794-3799.
69. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 2002, 3:753-766.
70. Inocencio N.M., Moehring J.M., Moehring T.J. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J. Biol. Chem. 1994, 269:31831-31835.
71. Henrich S., Cameron A., Bourenkov G.P., Kiefersauer R., Huber R., Lindberg I., Bode W., Than M.E. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat. Struct. Biol. 2003, 10:520-526.
72. Goyal A., Batra J.K. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem. J. 2000, 345(Pt 2):247-254.
73. Wang T., Zhao J., Ren J.L., Zhang L., Wen W.H., Zhang R., Qin W.W., Jia L.T., Yao L.B., Zhang Y.Q., Chen S.Y., Yang A.G. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res. 2007, 67:11830-11839.
74. Wang F., Ren J., Qiu X.C., Wang L.F., Zhu Q., Zhang Y.Q., Huan Y., Meng Y.L., Yao L.B., Chen S.Y., Xu Y.M., Yang A.G. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin. Cancer Res. 2010, 16:2284-2294.
75. Peterson J.J., Meares C.F. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug. Chem. 1998, 9:618-626.
76. Abu Ajaj K., Graeser R., Fichtner I., Kratz F. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother. Pharmacol. 2009, 64:413-418.
77. Yuan X., Lin X., Manorek G., Howell S.B. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer 2011, 11:61.
78. Mager D.E. Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 2006, 72:1-10.
79. Chen X., Lee H.F., Zaro J.L., Shen W.C. Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins. Mol. Pharm. 2011, 8:457-465.
80. van Kerkhof P., Strous G. The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem. Soc. Trans. 2001, 29:488-493.
81. Grant B., Donaldson J. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 2009, 10:597-608.
82. Muller-Eberhard U., Liem H., Grasso J., Giffhorn-Katz S., DeFalco M., Katz N. Increase in surface expression of transferrin receptors on cultured hepatocytes of adult rats in response to iron deficiency. J. Biol. Chem. 1988, 263:14753-14756.
83. Marqusee S., Baldwin R.L. Helix stabilization by Glu-. Lys+ salt bridges in short peptides of de novo design. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:8898-8902.
84. Argos P. An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J. Mol. Biol. 1990, 211:943-958.
85. Hu W., Li F., Yang X., Li Z., Xia H., Li G., Wang Y., Zhang Z. A flexible peptide linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion protein. J. Biotechnol. 2004, 107:83-90.